BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30305507)

  • 1. [Myelodysplastic syndromes and iron metabolism].
    Kawabata H
    Rinsho Ketsueki; 2018; 59(10):2042-2049. PubMed ID: 30305507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload in myelodysplastic syndromes (MDS).
    Gattermann N
    Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
    Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron overload in myelodysplastic syndromes.
    Mahesh S; Ginzburg Y; Verma A
    Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A variant erythroferrone disrupts iron homeostasis in
    Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
    Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
    Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
    Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron overload in patients with myelodysplastic syndromes: An updated overview.
    Moukalled NM; El Rassi FA; Temraz SN; Taher AT
    Cancer; 2018 Oct; 124(20):3979-3989. PubMed ID: 29905937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
    Cui R; Gale RP; Zhu G; Xu Z; Qin T; Zhang Y; Huang G; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
    Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA
    Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EnvIRONmental Aspects in Myelodysplastic Syndrome.
    Petzer V; Theurl I; Weiss G; Wolf D
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
    Steensma DP; Gattermann N
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
    Zeidan AM; Pullarkat VA; Komrokji RS
    Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.
    Cuijpers ML; Raymakers RA; Mackenzie MA; de Witte TJ; Swinkels DW
    Br J Haematol; 2010 May; 149(3):322-33. PubMed ID: 20067561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron overload in patients with myelodysplastic syndromes.
    Jensen PD
    Curr Hematol Malig Rep; 2007 Feb; 2(1):13-21. PubMed ID: 20425384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
    Cazzola M; Della Porta MG; Malcovati L
    Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S; Santini V; Musallam K; Taher A
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.